Form 4: Corcept Therapeutics Director Acquires Stock Options
Insider Transaction
Director James N. Wilson acquired 12,500 stock options in Corcept Therapeutics Inc. on May 21, 2026.
Summary
- Director James N. Wilson acquired 12,500 stock options for Corcept Therapeutics Inc. common stock.
- The options have an exercise price of $59.69 and were granted on May 21, 2026.
- These options vest ratably over a one-year period, monthly, starting from May 21, 2026, contingent on continued service.
- The expiration date for these options is May 21, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard stock option grant to a director, which is a common compensation practice and does not inherently signal a significant change in the company's prospects.
Positives
- Director acquisition of stock options can signal confidence in the company's future performance.
- The grant of options provides potential future equity ownership for a key executive.
Future Outlook
The stock options are exercisable over a one-year period starting May 21, 2026, and expire on May 21, 2036, indicating a long-term incentive for the director.
Industry Context
StockSavvy.ai notes that insider grants of stock options are common in the biotechnology and pharmaceutical sectors as a method to attract and retain executive talent and align their interests with shareholders.
Stakeholder Impact
- Shareholders: The grant of options does not immediately dilute share ownership but represents potential future dilution if exercised. It can also be seen as a positive alignment of director incentives.
- Employees: This transaction is specific to a director and does not directly impact other employees.
- Management: Reinforces standard compensation practices for executive and director roles.
Next Steps
- The director may exercise the stock options according to the vesting schedule and expiration date.
- The company will continue to operate under its existing business strategy.
Key Dates
| Date | Description |
|---|---|
| 05/21/2026 | Date of earliest transaction and grant date of stock options. |
| 05/21/2036 | Expiration date of the granted stock options. |
| 05/26/2026 | Date the statement was signed. |
Keywords
Corcept Therapeutics, CORT, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.